Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Capital Expenditures (2016 - 2025)

Regenxbio has reported Capital Expenditures over the past 11 years, most recently at -$1.0 million for Q4 2025.

  • Quarterly results put Capital Expenditures at -$1.0 million for Q4 2025, down 194.25% from a year ago — trailing twelve months through Dec 2025 was $889000.0 (down 63.51% YoY), and the annual figure for FY2025 was $889000.0, down 63.51%.
  • Capital Expenditures for Q4 2025 was -$1.0 million at Regenxbio, down from $491000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for RGNX hit a ceiling of $31.0 million in Q1 2021 and a floor of -$1.0 million in Q4 2025.
  • Median Capital Expenditures over the past 5 years was $2.0 million (2023), compared with a mean of $6.4 million.
  • Biggest five-year swings in Capital Expenditures: surged 570.0% in 2021 and later crashed 194.25% in 2025.
  • Regenxbio's Capital Expenditures stood at $14.6 million in 2021, then tumbled by 62.57% to $5.5 million in 2022, then crashed by 79.41% to $1.1 million in 2023, then decreased by 4.17% to $1.1 million in 2024, then crashed by 194.25% to -$1.0 million in 2025.
  • The last three reported values for Capital Expenditures were -$1.0 million (Q4 2025), $491000.0 (Q3 2025), and $391000.0 (Q2 2025) per Business Quant data.